Eylea Biosimilar Developer Momenta To Be Acquired By J&J For $6.5bn

M710 Aflibercept Candidate To Be Filed In 2021

 
• By Dean Rudge
  
Close-up of blue eye. High Technologies in the futuristic. : cataract
Momenta and Mylan's Eylea biosimilar is set to pass into J&J's hands • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business